About
Jacqualyn (Jackie) Fouse, Ph.D., has served as a member of the Agios board of directors since December 2017 and as board chair since August 2022. She also served as chief executive officer of Agios from February 2019 to August 2022.
Before her leadership at Agios, she served as president and chief operating officer of Celgene Corporation until April 2017, having joined Celgene in 2010 as chief financial officer and later becoming president of the company's global hematology and oncology franchise in 2014.
She earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington.
Roles
Agios Pharmaceuticals, Inc.
Chair of the Board · Current role
Dec 2017–present
Agios Pharmaceuticals
Chief Executive Officer · Chair of the board since August 2022.
Feb 2019 – Aug 2022
Dermavant Sciences
Executive Chair
Jul 2017 – Sep 2018
Celgene
President and Chief Operating Officer · Also served as president, hematology and oncology (2014–2016) and EVP & CFO (2012–2014).
Mar 2016 – Mar 2017
Celgene
EVP & Chief Financial Officer
Feb 2012 – Jul 2014
Bunge Limited
Chief Financial Officer
2007 – 2010
Alcon Laboratories
SVP & Chief Financial Officer · Later SVP, CFO and corporate strategy 2006–2007.
2002 – 2006
Agios
Chief Executive Officer · Led the company as CEO before transitioning to board chair.
Feb 2019 - Aug 2022
Celgene Corporation
President and Chief Operating Officer · Served until April 2017; joined in 2010 as CFO and became president of the global hematology and oncology franchise in 2014.
—
External Roles
Incyte Corporation
Director; audit and finance and nominating and corporate governance committees
—
Madrigal Pharmaceuticals
Director; audit, nominating and governance and compensation committees
—
Incyte Corporation
Board of Directors
—
Director Compensation
FY 2025
Fees earned or paid in cash
$92,500
Also at Agios Pharmaceuticals, Inc.